Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/TGTX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

TG Therapeutics Inc (TGTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

TGTX trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported robust revenue growth, with 2026 guidance raised to $950 million, though recent quarterly earnings missed estimates. High profitability margins and a consensus analyst price target of $64.00 suggest upside potential, supported by Briumvi's market expansion and upcoming clinical catalysts.
Outlook remains positive driven by Briumvi's growth and potential acquisition interest, but risks include earnings volatility, high valuation multiples, and competitive pressures in the multiple sclerosis market. Investors should weigh strong fundamentals against execution risks and market sentiment shifts.
Read full analysis

Key Stats

  • Market Cap
    $8.53B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $59.06
  • 52W Low
    $26.94
  • Typical Hold Time
    -
  • Enterprise Value
    $8.74B
  • Div Yield
    -
  • Trading Activity
    -
$54.77
52W Low: $26.94
12 Mar 2026
52W High: $59.06
09 Jul 2026

Track TG Therapeutics Inc (TGTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.94 and a high of $59.06, highlighting its annual price range. Buy and sell TG Therapeutics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Most Recent News

Content is generated by Aura AI

BMO downgrades Lululemon to Underperform amid legal probe and weak sales outlook

BMO Capital Markets initiated coverage of Lululemon Athletica with an Underperform rating and a $70 price target, citing weakening demand in key markets and margin pressures. This follows a 4% revenue decline in Q2 and a reduced full-year forecast. M...

Market News
2 hours ago
Stuart Mooney
Bearish
news icon
BMO downgrades Lululemon to Underperform amid legal probe and weak sales outlook

Core & Main beats Q2 revenue and EPS estimates, driven by municipal infrastructure demand.

Core & Main reported strong Q2 earnings with EPS of $0.94, surpassing the $0.92 analyst estimate and showing an 8% increase year-over-year. Revenue reached $2.15 billion, slightly above the $2.14 billion expected, supported by robust municipal infras...

Company Fundamentals
3 hours ago
Andrew Wynn
Bullish
news icon
Core & Main beats Q2 revenue and EPS estimates, driven by municipal infrastructure demand.

NJ American Water rates rise to fund $1.4B upgrades; PFAS credit offsets bills for eligible customers.

New Jersey American Water's rate increase, approved by the state's Board of Public Utilities, supports over $1.4 billion in water and wastewater infrastructure upgrades. Starting September 15, 2026, average residential water bills will rise by about ...

Market News
4 hours ago
PRNewsWire
Neutral
NJ American Water rates rise to fund $1.4B upgrades; PFAS credit offsets bills for eligible customers.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $8.53B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $59.06
  • 52W Low
    $26.94
  • Typical Hold Time
    -
  • Enterprise Value
    $8.74B
  • Div Yield
    -
  • Trading Activity
    -
$54.77
52W Low: $26.94
12 Mar 2026
52W High: $59.06
09 Jul 2026

Track TG Therapeutics Inc (TGTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.94 and a high of $59.06, highlighting its annual price range. Buy and sell TG Therapeutics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!